Seeing and treating cancer

Cancer Targeting Systems (CTS) is developing a new approach to cancer care, through innovative products that combine imaging and treating cancer, enabling clinicians and patients to make clearer choices.

Product

Combining imaging and therapy to deliver a new approach to cancer care.

Built on an innovative gene-based technology, CTS’s aim is a theranostic product that combines cancer cell imaging with therapy. Specific protein expression is triggered in cancer cells, leading to both the detection of the disease through scanning, but also the subsequent death of the tumour cells. The first step in development is a proof of concept clinical trial, demonstrating distribution of the product in the body and the specific expression of payload genes.

Platform

CTS draws on world-leading research and a series of exclusively licenced patents.

The platform behind CTS’s technology is a series of proprietary cancer cell specific gene promoters, which have been exclusively licenced from Johns Hopkins Medical School, Columbia University and Virginia Commonwealth University.

The principle of imaging cancer via a gene-based approach was originally demonstrated by scientific founders Professor Marty Pomper and Professor Paul Fisher in Nature Medicine in 2011. Non-viral gene-based therapeutics is an emerging area of interest - with the aim to deliver highly potent, cancer-cell specific products that can be widely distributed throughout the body.

The Team

Martin Pomper

Director

Co-scientific founder of CTS, practicing clinician and Professor of Radiology at Johns Hopkins University.

View profile

Will West

President & CEO

20 years’ experience of product discovery and development in biotech and pharma. BIA Board, BBSRC Council.

View profile

Jason R. Dinges

Director

Investor Director representing CTS’ main shareholder. Molecular biology background and qualified patent attorney.

View profile

News

CTS Inc. up and running

CTS is a new business focused on delivering cancer theranostic products - combining imaging with therapy. The lead platform is a gene-based technology based on cancer cell-specific gene promoters, licenced from Johns Hopkins University, VCU and Columbia University.

Read article View more news

Contact

Email: info@cts-bioscience.com
Telephone: +44 1799 531 130

Email us

UK operating address:
The Mansion, 
Chesterford Research Park 
Cambridge
CB10 1XL
UK

US registered address:
Cancer Targeting Systems, Inc.
1188 Centre Street
Newton Centre
Boston, MA 02459
USA

Seeing and treating cancer

Cancer Targeting Systems (CTS) is developing a new approach to cancer care, through innovative products that combine imaging and treating cancer, enabling clinicians and patients to make clearer choices.

Product

Combining imaging and therapy to deliver a new approach to cancer care.

Built on an innovative gene-based technology, CTS’s aim is a theranostic product that combines cancer cell imaging with therapy. Specific protein expression is triggered in cancer cells, leading to both the detection of the disease through scanning, but also the subsequent death of the tumour cells. The first step in development is a proof of concept clinical trial, demonstrating distribution of the product in the body and the specific expression of payload genes.

Platform

CTS draws on world-leading research and a series of exclusively licenced patents.

The platform behind CTS’s technology is a series of proprietary cancer cell specific gene promoters, which have been exclusively licenced from Johns Hopkins Medical School, Columbia University and Virginia Commonwealth University.

The principle of imaging cancer via a gene-based approach was originally demonstrated by scientific founders Professor Marty Pomper and Professor Paul Fisher in Nature Medicine in 2011. Non-viral gene-based therapeutics is an emerging area of interest - with the aim to deliver highly potent, cancer-cell specific products that can be widely distributed throughout the body.

The Team

Martin Pomper

Director

Co-scientific founder of CTS, practicing clinician and Professor of Radiology at Johns Hopkins University.

View profile

Will West

President & CEO

20 years’ experience of product discovery and development in biotech and pharma. BIA Board, BBSRC Council.

View profile

Jason R. Dinges

Director

Investor Director representing CTS’ main shareholder. Molecular biology background and qualified patent attorney.

View profile

News

CTS Inc. up and running

CTS is a new business focused on delivering cancer theranostic products - combining imaging with therapy. The lead platform is a gene-based technology based on cancer cell-specific gene promoters, licenced from Johns Hopkins University, VCU and Columbia University.

Read article View more news

Contact

Email: info@cts-bioscience.com
Telephone: +44 1799 531 130

Email us

UK operating address:
The Mansion, 
Chesterford Research Park 
Cambridge
CB10 1XL
UK

US registered address:
Cancer Targeting Systems, Inc.
1188 Centre Street
Newton Centre
Boston, MA 02459
USA